Rapid induction of apoptosis in chronic lymphocytic leukemia cells by the microtubule disrupting agent BNC105

Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukaemiain vivo

(2015) Darcy J. P. Bates et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Bim and VDAC1 are hierarchically essential for mitochondrial ATF2 mediated cell death

(2015) Zhaoyun Liu et al.   Cancer Cell International

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Jean-Yves Blay et al.   LANCET ONCOLOGY

Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function

(2014) Jessica J. Field et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Recent advances in vascular disrupting agents in cancer therapy

(2014) Elena Porcù et al.   Future Medicinal Chemistry

Gossypol Increases Expression of the Pro-apoptotic BH3-only Protein NOXA through a Novel Mechanism Involving Phospholipase A2, Cytoplasmic Calcium, and Endoplasmic Reticulum Stress

(2014) Ryan S. Soderquist et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC)

(2014) Marc C. Chamberlain et al.   JOURNAL OF NEURO-ONCOLOGY

Evolving Understanding of the CLL Genome

(2014) Michaela Gruber et al.   SEMINARS IN HEMATOLOGY

The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the BH3-only protein NOXA

(2013) Ryan Soderquist et al.   APOPTOSIS

Vinblastine Rapidly Induces NOXA and Acutely Sensitizes Primary Chronic Lymphocytic Leukemia Cells to ABT-737

(2013) D. J. P. Bates et al.   MOLECULAR CANCER THERAPEUTICS

Vinca alkaloids cause aberrant ROS-mediated JNK activation, Mcl-1 downregulation, DNA damage, mitochondrial dysfunction, and apoptosis in lung adenocarcinoma cells

(2012) Wei-Hsin Chiu et al.   BIOCHEMICAL PHARMACOLOGY

Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme

(2012) Kenneth F. Grossmann et al.   JOURNAL OF NEURO-ONCOLOGY

Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis

(2011) Darcy J.P. Bates et al.   CANCER BIOLOGY & THERAPY

Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation

(2011) D. Rischin et al.   CLINICAL CANCER RESEARCH

Multiple BH3 Mimetics Antagonize Antiapoptotic MCL1 Protein by Inducing the Endoplasmic Reticulum Stress Response and Up-regulating BH3-only Protein NOXA

(2011) Tina C. Albershardt et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Discovery of 7-Hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a Tubulin Polymerization Inhibitor with Potent Antiproliferative and Tumor Vascular Disrupting Properties

(2011) Bernard L. Flynn et al.   JOURNAL OF MEDICINAL CHEMISTRY

Mitosis is not a key target of microtubule agents in patient tumors

(2011) Edina Komlodi-Pasztor et al.   Nature Reviews Clinical Oncology

Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasms

(2010) Lena Reindl et al.   BRITISH JOURNAL OF HAEMATOLOGY

BNC105: A Novel Tubulin Polymerization Inhibitor That Selectively Disrupts Tumor Vasculature and Displays Single-Agent Antitumor Efficacy

(2010) G. Kremmidiotis et al.   MOLECULAR CANCER THERAPEUTICS

Phase I Clinical Trial of MPC-6827 (Azixa), a Microtubule Destabilizing Agent, in Patients with Advanced Cancer

(2010) A.-M. Tsimberidou et al.   MOLECULAR CANCER THERAPEUTICS

Vinblastine Induces Acute, Cell Cycle Phase–Independent Apoptosis in Some Leukemias and Lymphomas and Can Induce Acute Apoptosis in Others when Mcl-1 Is Suppressed

(2010) Bethany L. Salerni et al.   MOLECULAR CANCER THERAPEUTICS

Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells

(2009) Bi-ke Zhu et al.   ANTI-CANCER DRUGS

Antivascular Actions of Microtubule-Binding Drugs

(2009) E. L. Schwartz   CLINICAL CANCER RESEARCH

ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells

(2009) Q. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer Cells Display Profound Intra- and Interline Variation following Prolonged Exposure to Antimitotic Drugs

(2008) Karen E. Gascoigne et al.   CANCER CELL